{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093339","form_type":"8-K","ticker":"NTLA","cik":"0001652130","company_name":"Intellia Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.972950+00:00","generated_at":"2026-05-31T10:58:35.493751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Intellia Q2 net loss widens to $147M; NTLA-2002 Phase 2 meets endpoints, Phase 3 on track","bullets":["NTLA-2002 Phase 2 for HAE met primary and all secondary endpoints; 50 mg dose selected for pivotal Phase 3, on track to start 2H 2024.","Phase 3 MAGNITUDE trial (NTLA-2001 for ATTR-CM) enrolling rapidly across >12 countries and >35 sites.","Plans to initiate Phase 3 of NTLA-2001 for ATTRv-PN by year-end and dose first patient in NTLA-3001 Phase 1/2 for AATD in 2H 2024.","Q2 2024 net loss $147.0M vs $123.7M YoY; cash $939.9M expected to fund operations into late 2026.","Appointed Edward Dulac as CFO effective July 22 and Brian Goff to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093339","json":"https://secwatch.observer/filing/0000950170-24-093339.json","markdown":"https://secwatch.observer/filing/0000950170-24-093339.md","text":"https://secwatch.observer/filing/0000950170-24-093339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/0000950170-24-093339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1652130/000095017024093339/ntla-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:58:35.493751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}